Accelerating Access to Critical Therapies for ALS Act

S. 4867, Accelerating Access to Critical Therapies for ALS Act

Client expense: $100,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS)

ALS Disability Insurance Access Act (S.578/H.R.1407) to waive the five-month waiting period before people with ALS receive benefits under Social Security Disability Insurance. The Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act (S. 2741/ H.R. 4932) would expand access to telemedicine and telehealth for people with ALS through a legal and regulatory environment where providers are permitted to deliver safe, high quality care using telehealth and telemedicine regardless of care delivery location or technological method. Additionally, all changes made to expand access to telehealth during the COVID-19 public health emergency should be permanently extended. Promising Pathway Act (H.R. 7269/ S. 3872) to establish a new time-limited provisional approval path at the FDA for drug sponsors to market drugs that show promise while additional testing takes place and before full FDA approval is achieved. Accelerating Critical Therapies for ALS Act (H.R. 7071) reintroduced as H.R. 8662/ S. 4867 to create 1) a new framework for delivering experimental therapies to people with ALS; 2) a new research grant program at the FDA for rare neurodegenerative diseases, and; 3) a new Collaborative for Rare Neurodegenerative Diseases at the Department of Health and Human Services (HHS) to coordinate federal efforts on developing and approving effective treatments and cures.

Client expense: $23,681 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE